Get our latest issue now

available for iOS, Android & web

latest issue

Takeda files bowel disease drug vedolizumab in USA

Daily News | June 24, 2013

Kevin Grogan

Takeda files bowel disease drug vedolizumab in USA

Takeda Pharmaceutical Co has submitted its gut-selective monoclonal antibody vedolizumab for approval in the USA for moderately to severely active Crohn's disease and ulcerative colitis, the two most common forms of inflammatory bowel disease.

The filing to the US Food and Drug Administration is based on four Phase III trials which studied 2,700 patients in nearly 40 countries, making it the largest late-stage clinical trial programme conducted to date simultaneously evaluating both CD and UC. The GEMINI programme investigated the drug in patients who had failed at least one conventional therapy, including corticosteroids, immunomodulators and/or anti-tumour necrosis factor (TNF)-alpha therapy, such as AbbVie's Humira (adalimumab).

Vedolizumab is a novel alpha-4 beta-7 integrin antagonist which works by blocking a key inflammatory marker on white blood cells. Takeda acquired the drug with its $8.80 billion purchase of Millennium Pharmaceuticals in 2008 and a number of analysts believe the treatment, which was filed in Europe in March, has the potential to be a blockbuster.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Last chance to enter!